Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study

The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial

(2017) Karen C Johnson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus

(2016) Masakazu Haneda et al.   CLINICAL THERAPEUTICS

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Sarcopenic obesity

(2013) Matthew F. Bouchonville et al.   Current Opinion in Endocrinology Diabetes and Obesity

Association between Body-Mass Index and Risk of Death in More Than 1 Million Asians

(2011) Wei Zheng et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes: The Korean Sarcopenic Obesity Study (KSOS)

(2010) T. N. Kim et al.   DIABETES CARE